Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONAAccesswire • 11/06/23
Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private PlacementAccesswire • 09/25/23
With Orphan Drug Designation, Ainos' VELDONA Has Compelling Opportunity to Improve Quality of Life for HIV PatientsNewsfile Corp • 09/19/23
Ainos' VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive PatientsAccesswire • 09/18/23
Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry AdoptionAccesswire • 08/09/23
Ainos Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20M Revenue TargetAccesswire • 06/14/23
Ainos Launches New VELDONA Pet Lohas and Soothing Health Supplements, Catalyzing Its Drive to $20M Sales TargetAccesswire • 06/07/23
Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M in SalesAccesswire • 05/30/23
Ainos Signs Agreement Establishing Topmed as Exclusive Distributor of VELDONA Animal Health Supplements in TaiwanAccesswire • 03/21/23
Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate for Treatment of Oral Warts in HIV-Seropositive PatientsAccesswire • 03/14/23
Ainos and Tah-An Sign MoU to Explore Manufacture of VELDONA Animal Investigational New DrugAccesswire • 01/23/23